Objectives: To determine the factors associated with failure of noninvasive positive pressure ventilation (NPPV) in patients presenting with acute respiratory failure to the emergency department (ED).
Methods: The authors retrospectively analyzed patients admitted to the ED for acute respiratory failure (defined as a PaCO2 level >45 mm Hg, and pH < or = 7.35 or a PaO2/FiO2 ratio < 250 mm Hg) and who were treated with NPPV. NPPV was delivered routinely according to an institutional protocol. Failure of NPPV was defined as the requirement of endotracheal intubation at any time.
Results: A total of 104 patients were included. NPPV failed in 31% (32/104), and the mortality was significantly higher in this group (12/32 [44%]) compared with patients who were not intubated (2/72 [3%]) (p < 0.0001). Factors associated with failure of NPPV were Glasgow Coma Scale score < 13 at ED admission (odds ratio [OR], 3.67; 95% confidence interval [CI] = 1.33 to 10.07), pH < or = 7.35 (OR, 3.23; 95% CI = 1.25 to 8.31), and respiratory rate (RR) > or =20 min(-1) (OR, 3.86; 95% CI = 1.33 to 11.17) after one hour of NPPV. The negative predictive value for NPPV failure was 86% (95% CI = 70% to 95%) for RR > or =20 min(-1). In the multivariate analysis, pH < or = 7.35 and RR > or =20 min(-1) after one hour of NPPV were independently associated with NPPV failure (adjusted ORs, 3.51; 95% CI = 1.29 to 9.62 and 3.55; 95% CI = 1.13 to 11.20, respectively).
Conclusions: Patients with pH < or = 7.35 and an RR > or =20 min(-1) after one hour of NPPV had an increased risk of subsequent endotracheal intubation.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1197/j.aem.2005.07.018 | DOI Listing |
Anesthesiology
January 2025
Department of Anesthesiology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
Background: Tranexamic acid is an anti-fibrinolytic agent routinely used during hip and knee joint replacement surgery to minimize bleeding. Chronic kidney disease is a common chronic health problem seen among adults requiring major arthroplasty surgery. Tranexamic acid is renally cleared and may accumulate in chronic kidney disease.
View Article and Find Full Text PDFInt J Biol Macromol
January 2025
School of Chemical Engineering, Changchun University of Technology, Changchun 130012, China.
In this study, the dispersion behavior of MoS₂ in ionic liquids (ILs) with varying alkyl chain lengths was the primary focus of investigation, followed by the design of a novel PAM/SMA/CMC/PDA@MoS hydrogel. By optimizing the concentrations of CMC and PDA@MoS, a bifunctional hydrogel with both sensing and catalytic functions was successfully developed. Mechanical tests revealed that the PAM/SMA/CMC/0.
View Article and Find Full Text PDFJ Cardiovasc Magn Reson
January 2025
West Herts Teaching Hospitals NHS Trust, Watford, UK; Institute of Clinical Sciences, Imperial College, London, UK.
Objectives: To examine the provision of cardiovascular magnetic resonance (CMR) using gadolinium-based contrast agents (GBCA) in patients with chronic kidney disease (CKD).
Methods: An electronic survey was sent to the service leads of all CMR units in the UK in October 2022 requesting information on current departmental protocols and practice.
Results: A response rate of 55% was achieved from the 82 UK CMR units surveyed.
Med Phys
January 2025
Department of Medical Physics, Graduate School of Medical Sciences, Kindai University, Osakasayama, Osaka, Japan.
Background: Management of respiratory motion during radiation therapy is essential for accurate dose delivery and minimizing the risk to organs. In diagnostic imaging, respiratory monitoring is required for confirmation of breath-hold and four-dimensional computed tomography (CT) reconstruction. Although respiratory monitoring systems are widely used in radiation therapy, they are not often used for diagnostic imaging, where they could improve image quality.
View Article and Find Full Text PDFAnn Hematol
January 2025
Department of Hematology and Oncology, Japanese Red Cross Narita Hospital, Narita, Japan.
Renal impairment is reported in 20%-50% of patients with newly diagnosed multiple myeloma and is known as a poor prognostic factor. Although several studies have demonstrated that treatment with novel antimyeloma agents improves renal impairment and myeloma itself, the time-dependent clinical course of recovery of renal function has not been extensively studied. We retrospectively collected the data of characteristics and outcomes in consecutive unselected patients diagnosed with and treated for symptomatic multiple myeloma between January 2015 and December 2022, and extracted and analyzed the cases with renal impairment.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!